
çã®ã©ã³ããŒã¹ãã³ç ããèŠããŠããã¯ã¯ãã³åé¡
çã®ææçãã©ã³ããŒã¹ãã³ç ããåœå ã§åããŠç¢ºèªãããå®¶çäŒæç äºé²æ³ã«åºã¥ããçŠå²¡çã®çºçèŸ²å ŽããååŸ20ãã以å ã®50èŸ²å Žã«å¯ŸããŠãçãžã®ã¯ã¯ãã³æ¥çš®ãåœä»€ãããŸãããããã©ãããã®ã¯ã¯ãã³ã¯æ¥æ¬ã§ã¯æªæ¿èªã§ãããããŠæ³šç®ãã¹ãã¯ããã®ã¯ã¯ãã³ãæ¥çš®ããçã«ç±æ¥ããçèã¯ãã¢ã¡ãªã«ãžã®èŒžåºãèªããããŠããªããšããããšã§ãã
ãã©ã³ããŒã¹ãã³ç ãã®ã¯ã¯ãã³
11æã«ãæ¥æ¬ã§åããŠçã®ææçãã©ã³ããŒã¹ãã³ç ãã確èªãããŸããã12æ13æ¥æç¹ã§ãçŠå²¡çã®18èŸ²å Žã§ç¢ºèªã
çŠå²¡ã§çã®ææçãã©ã³ããŒã¹ãã³ç ããåœå å確èªãïŒïŒèŸ²å Žã«ã¯ã¯ãã³æ¥çš®ãåœä»€âŠäººã«ã¯ææãã
2024/11/19 07:34ãèªå£²æ°è
çŠå²¡çã¯ïŒïŒæ¥ãçã®ææçãã©ã³ããŒã¹ãã³ç ããåç糞島åžã®èŸ²å Žã§åœå ã§åããŠç¢ºèªããããšããŠãå®¶çäŒæç äºé²æ³ã«åºã¥ããçºçèŸ²å ŽããååŸïŒïŒãã以å ã®ïŒïŒèŸ²å Žã«å¯ŸããŠãçãžã®ã¯ã¯ãã³æ¥çš®ãåœä»€ããã
çã«ãããšãã©ã³ããŒã¹ãã³ç ã«ææãããšãçã®ç®èã«çµç¯ãã§ãããçºç±ããããããçã®èŽæ»çã¯ïŒïœïŒïŒ çšåºŠã§ãæ²»çåŸã¯åºè·ã§ãããææããçã®èãä¹³ã飲é£ããŠã人ã«ã¯ææããªããšããã
ãä»æïŒæ¥ã«çãæ€æ»ããç£å»åž«ããçã«é£çµ¡ããããïŒæ¥ã«åœã®æ©é¢ã®æ€æ»ã§ææã確èªããããïŒïŒæ¥çŸåšãåžå ïŒèŸ²å Žã§æ°åé ã®ææã確èªãããŠãããçã¯ä»å¹ŽåºŠæ«ãŸã§ã«çŽïŒïŒïŒïŒé ã«ã¯ã¯ãã³æ¥çš®ãè¡ãæ¹éã
ãçã®èŽæ»çã¯ïŒïœïŒïŒ çšåºŠã§ãæ²»çåŸã¯åºè·ã§ãããææããçã®èãä¹³ã飲é£ããŠã人ã«ã¯ææããªããããã§ããããä»å¹ŽåºŠæ«ãŸã§ã«ãçŽ5000é ã«ã¯ã¯ãã³æ¥çš®ãè¡ãæ¹éããšæžãããŠããŸãã
ãã®ã¯ã¯ãã³ã«é¢ãã 43äŒç»ããã®èšäºã«ã¯ãšãŠãéèŠãªããšãæžãããŠããã®ã§ããã倧æã¡ãã£ã¢ã®èšäºã§ã¯ãã®ããšã«ã¯è§ŠããããŠããŸããã
ãã®ãããæ°ã«ãªã£ãã®ã§ãããªãæéããããŠé¢é£æ å ±ãæãèµ·ãããŠã¿ãŸãããã§ããããªããªãæããããªè³æãèŠã€ãããªãã£ãã®ã§ã以äžã¯ç§ã®æšæž¬ãå«ãŸããŸããæããã«ééã£ãŠããããšãªã©ãããŸãããããã²ã³ã¡ã³ãã«ãŠãææãã ããã
é£ã®å®å šã«é¢ä¿ããŠããã®ã§ãçç£èŸ²å®¶ã ãã§ãªãç§ãã¡æ¶è²»è ãç¥ã£ãŠããå¿ èŠããããšæã£ãã®ã§ããã®ãã£ãããšããŠãŸãšããŠã¿ãŸããããã詳现ãªã©ããããŸãããããŸãèšäºã«ããããšæã£ãŠããŸãã
äžèšã¯ã43äŒç»ããã玹ä»ããŠããè³æã§ãã

䜿çšããã¯ã¯ãã³ã®è£œååã¯ããBovilis Lumpyvax-EãïŒMSD Animal Health瀟補ïŒã

å®éã«ãäžèšã®ãããªãç¥ãããåçã§åºãŠããŸãã
é·éççç£åºå ±ããã

ã¢ã¡ãªã«ã§ã¯ããã®ã¯ã¯ãã³ãæ¥çš®ããçã«ç±æ¥ããçèã ãã§ãªããã¯ã¯ãã³æ¥çš®ã宿œãããéœéåºçã§ã®é£Œé€æŽãããçãã茞éæã«æ¥çš®çãšåä¹ãããéæ¥çš®çããã¡ãšããããšã§ããææããçããã¡ãªã®ã¯ããããŸãããã¯ã¯ãã³ãæ¥çš®ããçããã¡ãªã®ã¯ãªããªã®ã§ããããã
åä¹ããã¡ãšããã®ã¯ãã¯ã¯ãã³ãæ¥çš®ããçã®åŒæ°ãªã©ããã¯ã¯ãã³æåãæåºãããŠãäŒæããå¯èœæ§ãèãã察çã®ããã«æããŸãããããå«ããŠããªããããŸã§å³ããããã®ãç¥ãããã£ãã®ã§ãããã¢ã¡ãªã«åŽãçºä¿¡ããŠãããã®ã§çããšãªããããªæ å ±ãèŠã€ããããšã¯ã§ããŸããã§ããã
èŠã€ãããªããšéã«çããã®ã§(ç¬)ãããããæãèµ·ãããŠã¿ãã®ã§ãããæ å ±ãããªãããšããããšãçããªã®ãããããªããšæããŸããã
12æ13æ¥ã«è¡ãããæ±è€èŸ²ææ°Žç£å€§è£ã®èšè äŒèŠã§ãã¢ã¡ãªã«ã®å¯Ÿå¿ã«ã€ããŠèªãããŸãããããªããããŸã§å³ããã®ãã¯æããã«ããŠããŸããã
ã¢ã¡ãªã«ã¯ãåœåã¯ãå šåœçã«èŒžå ¥åæ¢ãšããå³ããæ åºŠã瀺ããŠããŸããããããã亀æžã®çµæãã¯ã¯ãã³ïŒæ¥çš®ïŒçã®çŠå²¡ã®ã¿é§ç®ã§ããšãçŠå²¡ã«ã¯ç³ãèš³ãªãã§ãããã©ããããããããšã«ãªã£ãŠããã®ã§ãå šåœçãªåœ±é¿ã«ã¯è³ã£ãŠããªããšæããŸãã
ã«ã¿ãŒã«ã«ã€ããŠã¯ã11æ25æ¥ããçŠæ¢ã«ãªããŸãããããããã®åœã®å€æãªã®ã§ãé©åã§ãããšããäžé©åã§ãããšããæ¥æ¬æ¿åºããããèš³ã«ã¯ãããŸããããã¢ã¡ãªã«ããã®ãããªå·éãªåãæ¢ããããŠããã®ã§ããã£ãããšèŸ²æ°Žçã説æããŠãç±³åœã¯çŠå²¡ã ããçºççã ãã§ããšãå°åãåºåã£ãŠããŸãããããã¯ã ãã§ããšèª¬æããŠããã®çŠèŒžæªçœ®ãæ©ãã«è§£æ¶ã§ããããã«åªåããããšæããŸãã
çæ¬ã§ãçºçïŒ12æ13æ¥æç¹ã§2èŸ²å ŽïŒããŠããŸãããã¯ã¯ãã³åœä»€ã¯åºãŠããªãã®ã§ãä»ã®ãšããã¢ã¡ãªã«ãžã®èŒžåºãå¯èœã®ããã§ãããšããããšã¯ããã¯ãã¯ã¯ãã³ã«åé¡ããããšããããšã§ã¯ãªãã§ããããã
æ¥æ¬ã§ã®å¯©è°çµæ
2024幎2æ2æ¥ã«éå¬ãããã第269ååç©çšå»è¬åå°é調æ»äŒãã§ããã©ã³ããŒã¹ãã³ç çã¯ã¯ãã³ïŒBovilis Lumpyvax-EïŒãæ¥çš®ããçã«ç±æ¥ããé£åã®å®å šæ§ã«ä¿ãé£åå¥åº·åœ±é¿è©äŸ¡ã«ã€ããŠã話ãåãããããã§ãããéå ¬éã§è¡ãããŠããŸããã
ä»å¹Žã®2æã«éå¬ããŠããããšã¯ç¥ããŸããã§ããããä»ã®ç¶æ³ãèãããšæºåããããããããªæ°ãããŸãã
äžèšã®ããŒãžã«è°äºé²ã¯å ¬éãããŠããŸãããè³æïŒïŒïŒæ¡ïŒåç©çšå»è¬åè©äŸ¡æžãã©ã³ããŒã¹ãã³ç çã¯ã¯ãã³ïŒBovilis Lumpyvax-EïŒãæ¥çš®ããçã«ç±æ¥ããé£åã®å®å šæ§ãã¯ãéå ¬è¡šé åžè³æããšæžãããŠããŸãããªãå ¬è¡šã§ããªãã®ã§ããããã
2024幎2æ21æ¥ä»ã§ããã®å¯©è°çµæã«é¢ããããã³ã¡ãåéããŠããŸãããããã³ã¡åéãç¥ããŸããã§ããããçç£èŸ²å®¶ã®æ¹ãã¡ã¯æèŠãèšãæ©äŒãåŸãã®ã§ããããã
äžèšã¯ããã³ã¡åéæã®è³æã§ãã
ã©ã³ããŒã¹ãã³ç
çã¯ã¯ãã³ïŒBovilis Lumpyvax-EïŒãæ¥çš®ããçã«ç±æ¥ããé£åã®å®å
šæ§
è³æã«ã¯ãäžèšã®ããã«æžãããŠããŸãããLSDãã¯ãã©ã³ããŒã¹ãã³ç ã®ããšã§ãã
çŸåšåœå ã§æ¿èªãããŠãã LSD ã®ã¯ã¯ãã³ãååšããªãããšãåããçºçã«åããŠæµ·å€ã§è£œé ãããŠããã¯ã¯ãã³ãèŒžå ¥ã»åèããããšãæãŸãããšã®æèšããªããããšãšãã«ãåèã¯ã¯ãã³ã«ã€ããŠã¯ãæµ·å€ã§ã®äœ¿çšå®çžŸçãèžãŸããMSD AnimalHealth 瀟ïŒä»¥äžãMSD AH 瀟ããšãããïŒã補é ããã¯ã¯ãã³ãæšå¥šããããšããã§ããã
ä»è¬ãLSD ãåœå ã§çºçããéã«ãLSD çã¯ã¯ãã³ïŒBovilis Lumpyvax-EïŒãåœã»éœéåºçãç·æ¥çã«äœ¿çšããå¯èœæ§ãçããããšãèæ ®ããèŸ²ææ°Žç£çãããæ¬è£œå€ãæ¥çš®ããçã«ç±æ¥ããé£åã®å®å šæ§ã«ã€ããŠé£åå¥åº·åœ±é¿è©äŸ¡ã®å®æœãèŠè«ãããã
ïŒïŒäž»å€
匱æ¯åã©ã³ããŒã¹ãã³ç ãŠã€ã«ã¹ïŒLSDVïŒNeethling æ ªïŒ1 dose 1.0Ã10 4 TCID 50ïœ5.0Ã10 5 TCID 50ïŒïŒåç § 1ïŒ
ïŒïŒæ·»å å€ç
也ç¥è£œå€ã«ã¯ããªã³é žæ°ŽçŽ äºãããªãŠã ã»äºæ°Žåç©ããªã³é žäºæ°ŽçŽ ã«ãªãŠã ãã©ã¯ããŒã¹ã»äžæ°Žåç©åã³çç±æ¥ã®ãããã³ããæº¶è§£çšæ¶²ã«ã¯ããªã³é žæ°ŽçŽ äºãããªãŠã ã»äºæ°Žåç©ããªã³é žäºæ°ŽçŽ ã«ãªãŠã ãå¡©åãããªãŠã ãå¡©åã«ãªãŠã åã³æ³šå°çšæ°Žãå«ãŸããŠãããïŒåç § 1ã2ã3ïŒ
LSD ã¯ã¯ãã³ã®éçºã¯ 1999 幎ããè¡ããã2006 幎㫠LSD çã¯ã¯ãã³
ïŒLumpyvaxïŒãåã¢ããªã«ã§æ¿èªãããããã®åŸã2015 幎㫠Lumpyvax ã®ç»é²çã MSD-AHïŒIntervet South AfricaïŒç€Ÿã«å£²åŽããã2022 幎ããå瀟ããªã©ã³ãã®çç£æœèšã«ãã㊠GMP 1åã³ EU ã®å質管çèŠåã«åºã¥ããŠè£œé ããã¯ã¯ãã³ã®åç§°ã Bovilis Lumpyvax-E ãšãããBovilis Lumpyvax-E ã®çç£ã«äœ¿çšããã·ãŒãããã㯠Lumpyvax ã® LSDV ãã¹ã¿ãŒã·ãŒãç±æ¥ã§ãããã¯ã¯ãã³ã®çµæã¯ Lumpyvax ãšåäžã§ãããïŒåç § 2ã7ïŒ
åè¿°ã®ãšãããLumpyvax ã¯åã¢ããªã«ã«ãã㊠15 幎以äžç»é²ããªãããŠãããLumpyvax ã¯ã2006 幎ãã 2018 幎ã«ãããŠãåã¢ããªã«ã§ 2,700 äžããŒã¹ä»¥äžã䜿çšãããMSD-AH 瀟ã«ãã調æ»ã§ã¯ã2012 幎ãã 2017 å¹Žã®æéãæå®³äºè±¡ãçãããçäŸå ±åã¯ã»ãšãã©ãªããSuspected adverse reactionsïŒSARïŒã®çºççã¯éåžžã«å°ãªãïŒ1/10,000 æªæºïŒããšã瀺ãããŠãããïŒåç § 7ïŒ
Lumpyvax ã¯ãæ¬§å·æ±åéšïŒã®ãªã·ã¢ããã«ã¬ãªã¢çïŒã§ã䜿çšãããŠããã2016幎åã³ 2017 幎㫠230 äžããŒã¹ã販売ãããããŸããè¿å¹ŽïŒ2020ïœ2022 幎ïŒã¯æ±åã¢ãžã¢ïŒã«ã³ããžã¢ãã¿ã€ãå°æ¹ŸïŒã§ã Lumpyvax ã䜿çšãããŠãããæ¥æ¬åœå ã«ãããŠäœ¿çšå®çžŸã¯ãªããïŒåç § 7ïŒ
åç
§1ã2ã3ã7ãšæžãããŠããã®ã§ãããã©ããéå
¬è¡šãšãªã£ãŠããŸãã
1ïŒ SUMMARY OF PRODUCT CHARACTERISTICSïŒéå
¬è¡šïŒ
2ïŒ QALITY DOCUMENTATIONïŒéå
¬è¡šïŒ
3ïŒ SAFTY DOCUMENTATION(F)ïŒéå
¬è¡šïŒ
7ïŒ SAFETY DOCUMENTATION(A,B)ïŒéå
¬è¡šïŒ
Lumpyvax ãBovilis Lumpyvax-E ã¯ãã¢ã¡ãªã«ã§ã䜿çšãããŠããªããšèªã¿åããŸããã€ãŸããã¢ã¡ãªã«ã§ã¯ãã®ã¯ã¯ãã³ãæ¿èªãããŠããªãããã¯ã¯ãã³ã«é¢ããæ å ±ãçºä¿¡ãããŠããªããŠããã®ã¯ã¯ãã³ãæ¥çš®ããçã«ç±æ¥ããçèã¯èŒžå ¥ããªããšããããšãªã®ããªãšæããŸããã
çç£èŸ²å®¶ã®æ¹ãžã¯ããªãã¢ã¡ãªã«ããã®ãããªå¯Ÿå¿ãªã®ãã®èª¬æã¯ãã£ãã®ã§ããããããããåãã®æ¹ãããããæããŠããã ãããã§ãã
è°äºé²ïŒ3ããŒãžïŒã§æ°ã«ãªã£ãã®ã¯ãæ·»å å€ã«ã€ããŠãæ·»å å€çã®å«æéãèšèŒããŠããŸãããã¡ãã¯ãã¹ãã³ã°ã®å¯Ÿè±¡ãšãªã£ãŠãããŸãã®ã§ã埡åèæ å ±ãšããŠèšèŒãããŠããã ããŸããããšæžãããŠããéšåã§ããæ·»å å€çã®å«æéãšããã®ã¯ãå®å šæ§ã«é¢é£ããéèŠãªéšåã ãšæããŸãããããããã¹ãã³ã°ãã€ãŸãé»å¡ãã§èŠããªãããã«ããŠããã®ã¯ãªããªã®ã§ããããã
ããã«ãäžèšã®éšåãæ°ã«ãªããŸãã
çã¯ã¯ãã³ã®è©äŸ¡ã®é¢é£ã§ãããã¯äºåå±ã®ã»ãããç³ãäžããã®ã§ãããå¯é£éšã«ã¯ã¯ãã³æ ªãæ®çããªãããšãæããããŠãããŸããã
è©äŸ¡æžæ¡ã§ã¯ãããã«é¢ããæ å ±ãèŠåœãããŸãããã人ç£å ±éææçã§ã¯ãªãããšãæèšãããŠãããäž»å€ã®å®å šæ§ã«åé¡ã¯ãªããšããèãæ¹ã§ããããã£ãã§ãããããšããã³ã¡ã³ããé æŽããããŸããããã¡ãã¯äºåå±ããåçãããŠããã ããŸããäŸãã°ãéå»ã«é¶å€§è žèã®çã¯ã¯ãã³ãè©äŸ¡ããéã«ã¯ã確ãã«æ¥çš®åŸã®æ€äœããæ€åºãããªãããšãæ ¹æ ã«ããããšãããããŸããã§ããããã£ããããšãããéåžžã人ã«å¯Ÿããç åæ§ãããªãã®å¯©è°ãäžå¿ã«è¡ããŸããŠããªããšå€æãããã°æ®çãŸã§ã¿ãããšã¯ããããŸããã
ããã§ããäž»å€ã¯ããã©ã³ããŒã¹ãã³ç ãŠã€ã«ã¹ã®Neethlingæ ªãã«ãªããšæããŸãããããæ®çããŠãããããããªãããã©ã人ã«å¯Ÿããç åæ§ããªãããã確èªããªããŠããããšãã倿ã ãšèªã¿åããŸãã
ããã¯ã¯ãã³ãæ¥çš®ããŠäž»å€ãæ®çããŠããããã¯ã¯ãã³æ¥çš®ãããªãã§ææããçã®èãšåãããšã«ãªãã®ã§ã¯ãªãã§ããããããããé£ã¹ãããšã«ãªããªããèªç¶ã«ææããçã®èãšçµå±åãããšã§ããããæ·»å å€ããªãæ¹ãããããã«æãã®ã§ããã

äžèšã®è³æã«ããã©ã³ããŒã¹ãã³ç ã¯çä¹³ã®çç£çã«äžæçãªåœ±é¿ã¯ãããã人ã«ã¯ææãããçç£ç©ãé£çšäžå®å šããšæžãããŠããŸãããããŠããã»ãšãã©ã®çã¯ææããŠãåŸã ã«å埩ããããšãæžãããŠããŸãã
ã¯ã¯ãã³ãæ¥çš®ããŠäž»å€ã®ãŠã€ã«ã¹ãæ®ããããããªããããã¯ç¡èŠããŠãããŠãææããçã®ãŠã€ã«ã¹ã¯ç¡èŠã§ããªããšããã®ã¯ãççŸããŠããããã«æããŸãã
ãŸãã匱æ¯åããŠãããŸãã®ã§ãç©æ¥µçã«åç©ã®äœã®äžã§ã¯å¢ããªããšæãã®ã§ããã屿çãªãŠã€ã«ã¹ã®è€è£œãã¯ã¯ãã³æ ªã®è€è£œã¯ãããšæããŸããããŠã€ã«ã¹è¡çãèµ·ãããŠããªããšããããšã§ãã®ã§ãå¯é£éšã«ç©æ¥µçã«æ®ããšããå¯èœæ§ã¯ããªãäœãã®ã§ã¯ãªãããªãšèããããŸãã
ãå¯èœæ§ã¯ããªãäœãã®ã§ã¯ãªãããªãšèããããŸãããšããæšæž¬ã ãã§ããªãçŽåŸã§ããã®ã§ããããã

éåœã§ã¯ã1幎ããšã«å šé æ¥çš®ãç¶ç¶ããŠãããšæžãããŠããŸãã
ãã®ãããªããæ¹ã¯ã人éã®ã³ããã¯ã¯ãã³ãšåãã«æããŸããæ¬åœã«ãçç£èŸ²å®¶ãæ¶è²»è ã®ããã®æ¥çš®ãªã®ã§ããããã
ãã1ç¹æ°ã«ãªã£ãã®ã¯ãäžèšã®éšåã§ãã
å®ã®ãšããæè¿ã®æµè¡ã«ã€ããŸããŠã¯ãæç®çã«ã¯ïŒéãã®ãã¿ãŒã³ãããããã§ããããŸããŠãïŒã€ã¯å ã»ã©ã®åã¢ãžã¢ã§ã®çºçãããã¯éçã®ã©ã³ããŒã¹ãã³ç ãŠã€ã«ã¹ã«ãããã®ã§ãïŒã€ç®ã®ã¢ãžã¢çã ã§ããããã¯ãã«ã«ã³åå³¶ã§èµ·ãã£ãŠãããããªãã®ã«ã€ããŸããŠã¯ãã¢ããªã«ã§äœãããŠããã¯ã¯ãã³è£œå€ã«æ··å ¥ç©ããã£ãŠããããšã®éºäŒåçµ
æããèµ·ãã£ãŠå°ãç åæ§ãåºãŠããããšã«ãããã®ãšèšãããŠãããŸããããããã«ããŸããŠãã人ã«å¯Ÿããç åæ§ãå¢é²ããŠãããšããããšã¯å šãããããŸããã§ãç-çã§ç åæ§ã瀺ããŠãããšããããšãšãä»å埡審è°ã«ãªã£ãŠãããŸããã®Lumpyvaxãããã¯Lumpyvax-Eã«ã€ããŸããŠã¯ãéåžžã«æå¹æ§ãé«ããšããè«æããã«ã«ã³åå³¶ãããã¯æ±ã¢ãžã¢ã®æ¹ã ãããåºãŠãããŸããŠãä¿¡é Œæ§ã®é«ãã¯ã¯ãã³ãšèãããããšæããŸãã
ä»ãã¢ãžã¢çã§èµ·ããŠããæµè¡ã«ã€ããŠããã¯ã¯ãã³è£œå€ã«æ··å ¥ç©ããã£ãŠããããšã®éºäŒåçµæããèµ·ãã£ãŠå°ãç åæ§ãåºãŠããããšã«ãããã®ãšèšãããŠããããšæžãããŠããŸãããã®ããšããã¢ã¡ãªã«ãã¯ã¯ãã³ãæ¥çš®ããçããã¡ãšããçç±ã®1ã€ãªã®ãããããŸããã
è°äºé²ã§ã¯ããããã¯ã©ã³ããŒã¹ãã³ç ã®åŒ±æ¯æ ªã®åŸ®éã®æ··å ¥ã®ããã§ããããŸãããããããããæ¥çš®æã«åç©ã®äžã§çµæããèµ·ããããããªåœ¢ãªã®ããªãšãããããªããšãçãããŠããããã§ããããŸãããšç¶ããŠããããªãã ãä»äººäºã®ããã§ãã
é·ããªã£ãŠããŸããŸãããä»ã«ãæšå¯ãªã©ãå€ãã®ã§ãããå°ãæããŠãããŸãã
ãã¡ãã®è©Šéšã¯è«æããåŒçšãããã®ã§ããããŸããŠãå ·äœçã«äœ¿çšããçã®é æ°ã®åèšãå®ã¯æèšãããŠããŸãããããã¯ïŒã€ã®ã¯ã¯ãã³ã®
å¹æãæ¯èŒããè«æãªã®ã§ãããããããã®ã¯ã¯ãã³ã«å¯ŸããŠïŒé ã®çã䜿çšãããããïŒå詊éšãããšèšèŒãããŠããŸããåçŽèšç®ã§ïŒé æããïŒå詊éšã§28é ã ãããšæšå¯ããŠæ°å€ã远èšãããŠããã ããŠãããŸãããã¡ããèŸ²ææ°Žç£çã«åãåãããã®ã§ãããæ®å¿µãªããæåŸãŸã§æçãªåçããªãã£ããšãããäºåå±ããåŸ¡ææ¡ãªã®ã§ããã28é ãšæèšãããŠããªããšããããšãèæ³šã«èšèŒãããŠããã ããã°ãšæã£ãŠãããŸãã
çã®é æ°ã®åèšãæèšããŠããªããããªè«æãåŒçšããããã«ã€ããŠèŸ²ææ°Žç£çããã¯æçãªåçããªããªããŠããããªããšã§ããã®ã§ããããã
èæ¯ããŒã¿ãå ¥æãã¹ãèŸ²ææ°Žç£çã«ãåãåãããã®ã§ãããäœåã
ã®è©Šéšã2007幎ã«è¡ãããŠããã17幎åãšããããšããã£ãŠã宿œããã詊éšå Žã«ãããæµç£ã®çºçççã®æ å ±ãå ¥æããããšã¯æ®å¿µãªããã§ããŸããã§ããã
æµç£ã®çºççãéèŠã ãšæãã®ã§ããããå ¥æã§ããŸããã§ãããã§æžãŸããŠããã®ã§ãããããããã17幎åã®ããŒã¿ããªãæ°ããããŒã¿ããªãã®ã§ããããã
ã ã ã ã äŒ ç€Ÿ ã åº ã ㊠ã ã è³ æ äž ã¯ ã å ç § è³ æ ïŒ ã®Summary of product characteristicsã®äžã®3.12ãwithdrawal periodãããããäŒè¬æéã«ãªãã®ã§ãããèãä¹³ããŒããšããèšèŒã¯ããããŸããã§ãããããããã®ãŸãŸèŸ²ææ°Žç£çãåããã©ããã¯ãªã¹ã¯ç®¡çæ©é¢ã®æ±ºæã§ãã®ã§ããŸããããããã®ãªã¹ã¯è©äŸ¡æžã«èšèŒããã®ãé©åãã©ãããšãããšããã¯å®¿é¡ãšããŠæã¡åž°ãããŠãã ããã
ãäŒè¬æéããšã¯ãå»è¬åæ®çã®å¯èœæ§ãããçæ°Žç£ç©ïŒèãåµãçä¹³ãéãªã©ïŒãé£åãžéã°ããããšãé²ãããã«å®ããããæéã§ããããŒãããšããã®ã¯ãã©ãèããã°ããã®ã§ããããã
ããã³ã¡ã®çµæãå ¬éãããŠããŸãããããªããš2éããåºãŠããŸããã§ããã

çµæãïŒåºãããæèŠïŒ
ãããŠæçµçã«ããã®ãããªè©äŸ¡æžãšãªã£ãããã§ãã
ã¢ã¡ãªã«ã®çãžã®ã¯ã¯ãã³ã«å¯Ÿããèã
ã¢ã¡ãªã«ãçºä¿¡ãããBovilis Lumpyvax-Eãã«é¢ããæ å ±ã調ã¹ãäžã§ãéåžžã«è峿·±ãèšäºïŒJun 16, 2023ïŒãèŠã€ããŸãããä»åŸãã©ã³ããŒã¹ãã³ç äºé²ã®ã¯ã¯ãã³ã«ãé¢ãã£ãŠããå 容ã ãšæããŸãã
èçšçãžã®mRNAã¯ã¯ãã³äœ¿çšãšæ¶è²»è ã«å¯Ÿããå®å šæ§ã«ã€ããŠæžãããèšäºã§ãè³ææŽŸãšå察掟ãäž¡æ¹ã®å°éå®¶ã«ããèŠè§£ãæžãããŠããŸãã
èšäºã®äžã§ãUSCAïŒç±³åœçç£åäŒïŒãçºè¡šãããªãªãŒã¹ïŒAPRIL 19, 2023ïŒã®å 容ã«è§ŠããŠããŸãã
ãçŸåšãç±³åœã§ã¯èççšã®mRNAã¯ã¯ãã³ã¯èªå¯ãããŠããŸããããã®æè¡ã«ã€ããŠã¯ã»ãšãã©ç¥ãããŠããªããããåœå£äœã¯ã¿ã¹ã¯ãã©ãŒã¹ãçµæããäºå®ãšç§åŠã«åºã¥ãããã®åé¡ã®è©äŸ¡ãè¡ãäºå®ã§ãã
ç£å»åž«ã§R-CALF USAã®åç©è¡çå§å¡äŒå§å¡é·ã§ããThornsberryå士ã¯ãå®¶çãžã®mRNAã¯ã¯ãã³æ¥çš®ã«ã€ããŠæžå¿µã衚æããå€ãã®äººãã³ããã¯ã¯ãã³ã®å¯äœçšãå䜵çãçºçããæ»äº¡ããŠããäŸãããããšãææããmRNAã¯ã¯ãã³ã®å®å šæ§ãæããã«ãªããŸã§ã«ã¯äœå¹ŽããããŠããã«ç ç©¶ããå¿ èŠãããããšèªã£ãŠããŸãã
ããã«ãå®¶ççšã¯ã¯ãã³ã®å®å šæ§ãã¹ãã§ã¯ãäŒè¬æéãéèŠã§ããããšãæžãããŠããŸãã
USDAã¯ããäŒè¬æéã¯ãã¯ã¯ãã³æ¥çš®ãåããåç©ã®èãçä¹³ããŸãã¯äººéãæ¶è²»ãããã®ä»ã®è£œåãã¢ãžã¥ãã³ããã¯ã¯ãã³ã®åŸ®çç©ã«ããæ±æãåããŠããªãããšã確èªããããã®ãã®ã§ãããšè¿°ã¹ãŠãããããã¯ãã¯ã¯ãã³ãæäžããŠããåç©ã®ã©ã®éšåãããã¯ã¯ãã³ã®çè·¡ã確èªã§ããªãæéãæ±ºå®ããããã«æ€æ»ãè¡ãããããšãæå³ããã
USDAïŒã¢ã¡ãªã«åè¡åœèŸ²åç
ãã¹ãŠã®ã¯ã¯ãã³ã¯ãUSDA ã®æ¿èªãåããåã«ãå®å šæ§ãšæå¹æ§ã蚌æããèšåºè©Šéšãåããªããã°ãªããªãããã¡ã«ã¯ç€Ÿã® Sequivity (saRNA ã¯ã¯ãã³) ã¯çŸåšãè±ã®è±ã€ã³ãã«ãšã³ã¶äºé²ã®ããã«åç©ãžã®åŠæ¹ç®ã«ãã䜿çšãèªå¯ãããŠãã saRNA ã¯ã¯ãã³ã§ãããšVerhoeven æ°ã¯ææããã
çèã«mRNAã¯ã¯ãã³ã¯ãŸã 䜿çšãããŠããªãããã§ãããè±èã«ã¯ãã§ã«ãè±ã€ã³ãã«ãšã³ã¶äºé²saRNAã¯ã¯ãã³ãSequivityãã®äœ¿çšãèªå¯ãããŠããŸãã
ãSequivityãã¯saRNAãšæžãããŠããã®ã§self-amplifyingãã€ãŸãèªå·±å¢æ®åïŒã¬ããªã³ã³ïŒã¯ã¯ãã³ãªã®ã ãšæããŸãã
2018幎ã«ã¯ãè±çšã®èªå·±å¢æ®åã¯ã¯ãã³ããã§ã«å®çšåãããŠãããšã¯ç¥ããŸããã§ãããã¢ã¡ãªã«ã§ã¯ãã©ããããæ¥çš®ãããŠããã®ã§ããããã
äžèšã®èšäºïŒ May 17, 2023 ïŒã«ã¯ããSequivityã¯çŸåšãåç©ãžã®äœ¿çšãèªå¯ãããŠããå¯äžã®saRNAã¯ã¯ãã³ã§ããããšæžãããŠããŸãããšããããšã¯ãè±ã®æ¬¡ã«ã¬ããªã³ã³ã¯ã¯ãã³ãæ¿èªãããã®ã¯æ¥æ¬äººãšããããšã«ãªãã®ã§ããããã
ãSequivityãã«ã€ããŠã¯ãäžèšã®èšäºïŒJuly 24, 2018ïŒã«è©³ããæžãããŠããŸãã詳ããèŠãäœåããªãã®ã§ããã5.2 Probability of human exposureããªã©ãæ°ã«ãªããŸãã
åç©çšã¯ã¯ãã³å©çšã®æåŒãïŒè±çšã¯ã¯ãã³ç·šïŒïŒç¬¬2çïŒïŒç¬¬3 è±çšã¯ã¯ãã³ç¬¬2çïŒïŒä»€å6幎3æïŒããèŠããšãæ¥æ¬ã§ã¯ã京éœåŸ®ç ãè±ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãïŒ14ããŒãžïŒãšããã«ã·ã¥ã¢ïŒ¥ïŒ² ãïŒ35ããŒãžïŒãè±ã€ã³ãã«ãšã³ã¶äºé²ãšããŠäœ¿ãããŠããããã§ãã
é·ããªã£ãŠããŸããŸãããããªãŒã¹ãã©ãªã¢ã§ã¯ã©ã³ããŒã¹ãã³ç äºé²RNAã¯ã¯ãã³ã®ç ç©¶ãé²ããããŠããŸãã
é¢å¿ãæããªããã°ãç¥ããªããã¡ã«ç§ãã¡ã®é£ç掻ã«ã©ãã©ãRNAã¯ã¯ãã³ãå ¥ã蟌ãã§ããã§ããããç¹ã«ãã¡ã«ã¯ç€ŸïŒMSD瀟ïŒã¯ãHPVã¯ã¯ãã³ã§ãããããåé¡ãããã®ã§ãå®¶ççšã®ã¯ã¯ãã³ã«ãé¢å¿ãæã€å¿ èŠããããšæããŸãã